Advancing cancer immunology & therapy: The promise of hormone therapy.

Aula Ammar*

Department of Surgery, University of Kansas Medical Center, Kansas, USA

Introduction

Cancer continues to be a significant global health burden, affecting millions of lives and challenging medical researchers and clinicians worldwide. Over the years, traditional cancer treatments such as chemotherapy, radiation, and surgery have shown efficacy, but they often come with adverse effects and limited success against certain cancer types. In recent decades, cancer immunology and therapy have emerged as groundbreaking approaches, harnessing the body's immune system to target and eradicate cancer cells effectively. Among these revolutionary strategies, hormone therapy has emerged as a promising avenue for improving cancer treatment outcomes [1].

Cancer immunology aims to unravel the complex interactions between cancer cells and the immune system. Unlike traditional treatments that directly target cancer cells, immunotherapy focuses on empowering the immune system to recognize and eliminate cancer cells more effectively. This field of research has led to the development of various immunotherapies, such as immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapy, which have demonstrated remarkable success in clinical trials against several types of cancer [2].

Hormone therapy, also known as endocrine therapy, is an established approach used in the treatment of hormone receptor-positive cancers. Many cancers, such as breast cancer and prostate cancer, depend on specific hormones, like estrogen and testosterone, for their growth and survival. Hormone therapy works by disrupting these hormone signals or blocking hormone receptors on cancer cells, thereby slowing down tumor growth or even inducing cancer cell death. Breast cancer is the most common cancer in women worldwide. A significant proportion of breast cancer cases are hormone receptor-positive, indicating that they respond to hormones like estrogen or progesterone. Hormone therapy has demonstrated impressive results in reducing tumor size, preventing recurrence, and improving survival rates in hormone receptor-positive breast cancer patients. Drugs like tamoxifen and aromatase inhibitors are commonly used to treat breast cancer through hormone therapy [3].

Prostate cancer, affecting men, is another hormone-driven malignancy. The growth and progression of prostate cancer cells are fueled by androgens, particularly testosterone. Hormone therapy for prostate cancer involves reducing the levels of testosterone or blocking its interaction with the androgen receptor. This can slow down tumor growth and provide palliative relief in advanced cases. Intriguingly, emerging research suggests that hormone therapy may have broader implications in cancer immunology beyond its direct effects on hormone receptor-positive cancers. Studies have indicated that hormone receptors are also present on immune cells, and manipulating these receptors through hormone therapy might modulate immune responses. This opens up new avenues for combination therapies that harness both hormone therapy and immunotherapy to enhance the immune system's ability to recognize and attack cancer cells [4, 5].

Conclusion

In the relentless pursuit of effective cancer treatments, the field of Cancer Immunology & Therapy has emerged as a promising frontier. Harnessing the power of the body's immune system to target and eliminate cancer cells has shown great potential, leading to significant advancements in recent years. One such breakthrough avenue is the integration of Hormone Therapy into cancer immunotherapies. This strategic combination offers new hope in the fight against various cancer types, paving the way for improved patient outcomes and better quality of life. Cancer immunotherapy has revolutionized cancer treatment by enabling the immune system to identify and attack cancer cells specifically. By leveraging the immune system's inherent ability to distinguish between healthy and abnormal cells, therapies like immune checkpoint inhibitors and adoptive T cell therapies have shown remarkable success in various malignancies, including melanoma, lung cancer, and certain types of leukemia.

References

1. Ruffell B, Chang-Strachan D, Chan V, et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer cell. 2014;26(5):623-37.
2. Broz ML, Binnewies M, Boldajipour Bet al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer cell. 201;26(5):638-52.
3. Mittal D, Gubin MM, Schreiber RD, et al. New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16-25.

***Correspondence to:** Aula Ammar, Department of Surgery, University of Kansas Medical Center, Kansas, USA. E-mail: aula.a@kumc.edu

***Received:** 26-Jul-2023, Manuscript No. AAJCIT-23-109840; **Editor assigned:** 28-Jul-2023, PreQC No. AAJCIT-23-109840 (PQ); **Reviewed:** 11-Aug -2023, QC No AAJCIT-23-109840; **Revised:** 16-Aug -2023, Manuscript No. AAJCIT-23-109840 (R); **Published:** 23-Aug -2023, DOI:10.35841/aajcit-6.4.156*

***Citation:** Ammar A, Advancing cancer immunology & therapy: The promise of hormone therapy. J Cancer Immunol Ther. 2023; 6(4):156*

4. Böttcher JP, e Sousa CR. The role of type 1 conventional dendritic cells in cancer immunity. Trends Cancer. 2018;4(11):784-92.

5. Binnewies M, Mujal AM, Pollack JL, et al. Unleashing type-2 dendritic cells to drive protective antitumor CD4+ T cell immunity. Cell. 2019;177(3):556-71.